Technical Analysis for 0D1W - Biophytis
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 9.52% | |
| Expansion Breakdown | Bearish Swing Setup | 9.52% | |
| Narrow Range Bar | Range Contraction | 9.52% | |
| New 52 Week Low | Weakness | 9.52% | |
| Wide Bands | Range Expansion | 9.52% | |
| Oversold Stochastic | Weakness | 9.52% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | 1 day ago |
| Up 10% | 1 day ago |
| Up 5% | 1 day ago |
| Up 3% | 1 day ago |
| Rose Above 10 DMA | 1 day ago |
Get this analysis on your stocks daily!
Biophytis Description
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Classification
Keywords: Biotechnology Muscular Dystrophy Covid 19 Duchenne Muscular Dystrophy Stargardt Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.0318 |
| 52 Week Low | 0.0021 |
| Average Volume | 1,981,370 |
| 200-Day Moving Average | 0.01 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 0.00 |
| Average True Range | 0.00 |
| RSI (14) | 53.49 |
| ADX | 17.82 |
| +DI | 26.53 |
| -DI | 20.41 |
| Chandelier Exit (Long, 3 ATRs) | 0.00 |
| Chandelier Exit (Short, 3 ATRs) | 0.00 |
| Upper Bollinger Bands | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.29 |
| BandWidth | 53.85 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.00 | ||||
| Resistance 3 (R3) | 0.00 | 0.00 | 0.00 | ||
| Resistance 2 (R2) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Resistance 1 (R1) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Pivot Point | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Support 1 (S1) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Support 2 (S2) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Support 3 (S3) | 0.00 | 0.00 | 0.00 | ||
| Support 4 (S4) | 0.00 |
